autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy (University of Navarra)

N/A

Report date: 2025/04/03 15:55:59

Base Information

Drug Nameautologous VitD3 tolerogenic monocyte-derived dendritic cell therapy (University of Navarra)
Drug Alias Nameautologous dendritic cell therapy (University of Navarra)tolDC-VitD3
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionVitamin D receptor agonists
TargetsVitamin D receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Navarra
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Navarra
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A